NCT01241331已完成2 期
A Randomized, Controlled Evaluation of the Safety and Efficacy of a Topical Treatment for Moderate-Severe Facial Acne Vulgaris
Braintree Laboratories20 个研究点 分布在 1 个国家目标入组 233 人开始时间: 2010年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 233
- 试验地点
- 20
- 主要终点
- percent reduction of total acne lesion counts
研究概览
简要总结
The purpose of this study is to compare the safety and efficacy of formulation BLI1100 to its vehicle in the treatment of moderate-severe acne vulgaris.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 45 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Qualifying Investigator's Global Assessment severity score
- •Qualifying number of non-inflammatory lesions
- •Qualifying number of inflammatory lesions
排除标准
- •Facial hair (beard), excessive scarring, sunburn or other disfigurement that may obscure the accurate assessment of acne grade
- •Using medications that are reported to exacerbate acne
- •Any clinically relevant finding at their baseline physical examination or dermatological medical history such as severe systemic diseases or diseases of the facial skin
- •Have a known hypersensitivity or previous allergic reaction to any of the components
- •Patients who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
- •Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures
研究组 & 干预措施
BLI1100
Experimental
BLI1100 topical cream
干预措施: BLI1100 (Drug)
Vehicle cream
Placebo Comparator
Vehicle topical cream
干预措施: Vehicle cream (Drug)
结局指标
主要结局
percent reduction of total acne lesion counts
时间窗: 12 weeks
次要结局
- Investigator's Global Assessment(12)
- Change in serum chemistry(12 weeks)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne VulgarisAcne VulgarisNCT02604680Braintree Laboratories509
已完成
2 期
BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne VulgarisAcne VulgarisNCT01815450Braintree Laboratories369
已完成
1 期
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120NeoplasmsNCT00715403Boehringer Ingelheim41
已完成
1 期
Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's DiseaseAlzheimer's DiseaseNCT01397539Biogen53
已完成
2 期
A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental FatSubmental FatNCT0515495510xBio, LLC51